Architects of immunity: How dendritic cells shape CD8 + T cell fate in cancer
Top Cited Papers
- 17 January 2025
- journal article
- review article
- Published by American Association for the Advancement of Science (AAAS) in Science Immunology
- Vol. 10 (103) , eadf4726
Abstract
Immune responses against cancer are dominated by T cell exhaustion and dysfunction. Recent advances have underscored the critical role of early priming interactions in establishing T cell fates. In this review, we explore the importance of dendritic cell (DC) signals in specifying CD8 + T cell fates in cancer, drawing on insights from acute and chronic viral infection models. We highlight the role of DCs in lymph nodes and tumors in maintaining stem-like CD8 + T cells, which are critical for durable antitumor immune responses. Understanding how CD8 + T cell fates are determined will enable the rational design of immunotherapies, particularly therapeutic cancer vaccines, that can modulate DC–T cell interactions to generate beneficial CD8 + T cell fates.Keywords
This publication has 228 references indexed in Scilit:
- CD8 T‐cell diversification: Asymmetric cell division and its functional implicationsEuropean Journal of Immunology, 2023
- Cxcr3 constrains pancreatic cancer dissemination through instructing T cell fateCancer Immunology, Immunotherapy, 2022
- Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung CancerCancer Cell, 2018
- Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell TherapyCancer Cell, 2017
- Critical Role for CD103+/CD141+ Dendritic Cells Bearing CCR7 for Tumor Antigen Trafficking and Priming of T Cell Immunity in MelanomaCancer Cell, 2016
- Dissecting the Tumor Myeloid Compartment Reveals Rare Activating Antigen-Presenting Cells Critical for T Cell ImmunityCancer Cell, 2014
- Macrophage IL-10 Blocks CD8+ T Cell-Dependent Responses to Chemotherapy by Suppressing IL-12 Expression in Intratumoral Dendritic CellsCancer Cell, 2014
- Type‐I IFN drives the differentiation of short‐lived effector CD8+ T cells in vivoEuropean Journal of Immunology, 2011
- A brief history of CD8 T cellsEuropean Journal of Immunology, 2007
- Priming of naive CD8+ T cells in the presence of IL-12 selectively enhances the survival of CD8+CD62Lhi cells and results in superior anti-tumor activity in a tolerogenic murine modelCancer Immunology, Immunotherapy, 2007